Integral Diagnostics (IDX) investor relations material

Opening remarks and agenda

• AGM opened at 10:00 a.m. after quorum confirmation; held in person and virtually, with poll voting on all resolutions.

• Agenda covered Chair and CEO addresses, formal resolutions, shareholder questions and voting; FY26 financial report was presented for consideration.

• First AGM as Managing Director and CEO, after just under three months in the role; outlined initial observations, actions underway, Q1 trading and FY27 outlook.

Financial performance review

• FY26 revenue rose 25.6% to AUD 788.7m, operating EBITDA rose 30.3% to AUD 164.8m, and operating EBITDA margin expanded 80 bps to 20.9%.

• FY26 operating NPAT increased 50.2% to AUD 47.4m; statutory NPAT was AUD 22.0m; operating diluted EPS rose 23.6% to AUD 0.126. Capitol Health merger synergies exceeded AUD 14m.

• Net debt was AUD 298.9m and pre-AASB 16 net debt/EBITDA was 2.3x at 30 June 2026, versus 2.6x a year earlier.

• Q1 FY27 revenue grew 3.0%, or 4.4% excluding closed sites and on a constant-currency basis; FY27 revenue growth guidance is 4%-6%.

• FY27 operating EBITDA margin guidance is 19.5%-20.5%, with improvement expected in H2; capex guidance is AUD 50m-AUD 60m.

Board and executive committee updates

• Jason Martinez became Managing Director and CEO in August 2026; Jenny Martin joined as CFO in October after becoming available earlier than expected.

• Craig White retired as CFO after FY26 results; a new General Manager for Victoria, appointed in September 2026, brought more than 25 years of industry experience.

• Chair credited succession planning and thorough handovers with supporting leadership continuity; Ian Kadish was acknowledged for eight years of leadership, including scaling the business and completing the Capitol Health merger.

• Raelene Murphy resigned as Audit Committee Chair in March after nine years on the board; Laura McBain took over the role.

• Toby Hall and Ingrid Player stood for re-election as directors.